Press coverage about Array BioPharma (NASDAQ:ARRY) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Array BioPharma earned a news impact score of 0.20 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.7530643067883 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Several research analysts recently weighed in on ARRY shares. BidaskClub raised shares of Array BioPharma from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. ValuEngine raised shares of Array BioPharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. J P Morgan Chase & Co raised shares of Array BioPharma from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $9.00 to $10.00 in a report on Wednesday, May 3rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 target price on shares of Array BioPharma in a report on Thursday, August 10th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $13.00 target price on shares of Array BioPharma in a report on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the company. Array BioPharma currently has a consensus rating of “Buy” and a consensus price target of $11.65.

Shares of Array BioPharma (NASDAQ ARRY) traded down 0.64% during mid-day trading on Wednesday, reaching $9.33. 1,105,012 shares of the company’s stock traded hands. Array BioPharma has a 12-month low of $3.18 and a 12-month high of $13.40. The company’s market cap is $1.60 billion. The company’s 50 day moving average is $8.36 and its 200 day moving average is $8.94.

Array BioPharma (NASDAQ:ARRY) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.04. The firm had revenue of $33.80 million for the quarter, compared to analysts’ expectations of $28.64 million. Array BioPharma had a negative net margin of 77.44% and a negative return on equity of 1,187.18%. The firm’s revenue was down 21.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.17) EPS. On average, analysts predict that Array BioPharma will post ($0.97) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/array-biopharma-arry-earns-daily-news-sentiment-rating-of-0-20/1532238.html.

About Array BioPharma

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Insider Buying and Selling by Quarter for Array BioPharma (NASDAQ:ARRY)

Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.